HDAMM-predictor: prediction of progression in asymptomatic myeloma patients
<|begin_of_text|><|start_header_id|>system<|end_header_id|> You are a research archivist expert in dataset metadata. Answer the question truthfully.  <|eot_id|><|start_header_id|>user<|end_header_id|> Here is the Description of a dataset. Description:'The HDAMM-predictor is based on microarray gene expression and predicts the risk of progression from asymptomatic to symptomatic myeloma. It divides the patients in three groups, from low to high risk to progress. It was generated according to the method published by Rème et al. 2013. Gene expression profiles of 259 asymptomatic myeloma patients were used as trainingset' . Please return only a json list of at most 3 Keywords corresponding to the Description:.<|eot_id|><|start_header_id|>assistant<|end_header_id|> {"Answer" : ["Asymptomatic myeloma","Multiple myeloma","Prognosis","Progression","Risk prediction"]} <|eot_id|>
 Here is the Description of a dataset. Description:'The HDAMM-predictor is based on microarray gene expression and predicts the risk of progression from asymptomatic to symptomatic myeloma. It divides the patients in three groups, from low to high risk to progress. It was generated according to the method published by Rème et al. 2013. Gene expression profiles of 259 asymptomatic myeloma patients were used as trainingset' . Please return only a json list of at most 3 Keywords corresponding to the Description:.
The HDAMM-predictor is based on microarray gene expression and predicts the risk of progression from asymptomatic to symptomatic myeloma. It divides the patients in three groups, from low to high risk to progress. It was generated according to the method published by Rème et al. 2013. Gene expression profiles of 259 asymptomatic myeloma patients were used as trainingset
Asymptomatic myeloma; Multiple myeloma; Prognosis; Progression; Risk prediction